DGAP-News: VENITI, Inc. Announces First Uses of Veniti Vici

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jan 23, 2014 at 5:30 PM

DGAP-News: VENITI, Inc. Announces First Uses of Veniti Vici Venous Stent System

DGAP-News: VENITI, Inc. / VENITI, Inc. Announces First Uses of Veniti Vici Venous Stent System 23.01.2014 / 23:19 --------------------------------------------------------------------- Live Case Demonstration Scheduled for Leipzig Interventional Course (LINC) ST. LOUIS, 2014-01-23 23:19 CET (GLOBE NEWSWIRE) -- VENITI announced today that patients in the European Union (EU) were successfully treated for symptomatic venous outflow obstruction of the lower extremities with the Veniti Vici(tm) Venous Stent System. These procedures mark the first uses in patients of this novel Venous Stent from VENITI. More procedures using the Veniti Vici Venous Stent System are scheduled at various locations in the EU, including a live case demonstration at the Leipzig Interventional Course (LINC) on 28 January 2014. The Veniti Vici Venous Stent was designed from inception to be compatible with the unique anatomy and pathology of the venous system to specifically address the unmet need for a dedicated venous stent. Hundreds of thousands of people around the world suffer from lower-extremity venous disease, and until recently, the only treatment options available involved the use of re-purposed vascular stents originally designed for use in the arterial system, which physicians know is vastly different from the venous system in terms of hemodynamics, physiology, pathophysiology and other important characteristics. Mr. Stephen Black, a Consultant Vascular Surgeon at the prestigious St. George's Vascular Institute, St. George's Hospital, London, implanted Veniti Vici Stents in five patients on 14 and 15 January. 'The Veniti Vici Venous Stent appears to have the radial strength and vein coverage to provide optimal results in patients with symptomatic outflow obstruction of the lower extremities,' said Mr. Black. 'Having a stent that was designed from its inception for use in veins makes this an important addition to my treatment options.' Dr. Peter Neglen, a noted pioneer in venous stenting, who was also present at St Georges on 14 and 15 January commented: 'The Veniti Vici Stent placement today in patients represented the culmination of years of working with venous stent designs to better suit the unique characteristics of the venous anatomy and venous disease.' Dr. Gerard O'Sullivan at the prominent Galway University Hospitals, Galway, Ireland who implanted the Veniti Vici stent on 16 January also commented that 'The Veniti Vici Venous Stent is a step forward in venous stenting to help treat patients suffering from venous outflow obstruction.' 'We are pleased that the unique advantages of a stent designed specifically for the venous system--including end-to-end crush resistance, higher radial resistive force, flexibility, and continuous vein coverage--are available to physicians treating venous outflow obstructions in the lower extremities,' noted Scott Solano, VENITI President and Chief Executive Officer. 'We believe the Veniti Vici Stent offers significant patient benefit due to its venous-specific design.' Mr. Solano and Daniel Krelle, VENITI European Marketing Director, will attend LINC 28-31 January and will be available to meet attendees and the media at the VENITI booth (Number 37). About VENITI, Inc. VENITI is a leading provider of innovative medical devices singularly focused on venous care. With three product lines: The Veniti Vici(tm) Venous Stent System, the Veniti Veni(tm) RF Plus Ablation System, and the Veniti Vidi(tm) Inferior Vena Cava (IVC) Filter System, VENITI is offering significant benefit to patients who suffer from lower extremity venous outflow obstruction or varicose veins, as well as those at risk of pulmonary embolism. The Veniti Vici(tm) Venous Stent System is CE Marked under the European Medical Device Directive (MDD) 93/42/EEC, and VENITI is seeking approval from the U.S. Food and Drug Administration (FDA) to begin clinical studies of the device in the United States. The Veniti Veni(tm) RF Plus Endovascular Ablation System is also CE Marked under the European Medical Device Directive (MDD) 93/42/EEC. The Veniti Vidi(tm) IVC Filter System is in early stages of clinical studies in New Zealand, and VENITI is seeking approval from the US FDA to begin clinical studies of the device in the United States. VENITI Headquarters is located in St. Louis, Missouri, USA while its Research & Development and Manufacturing divisions are located in Fremont, California, USA. For more information, call +1 314 282 3753 or visit www.veniti.com. Company Contact: Scott Solano +1 (314) 338 3019 The Veniti Vici Venous Stent System is CE Marked under the European Medical Device Directive (93/42/EEC); it is not available for sale in the United States. VENITI, the VENITI logo, and VENITI VICI are trademarks of VENITI, Inc. Media Contact: Daniel Krelle +44 7562 600 555 dkrelle@veniti.com News Source: NASDAQ OMX End of Corporate News --------------------------------------------------------------------- 23.01.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: VENITI, Inc. United States End of News DGAP News-Service --------------------------------------------------------------------- 249389 23.01.2014

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Americans' Faith in Democracy Hits New Lows

Polarization Beyond Politics: A National Reckoning When you catch wind of a report like this one, it's enough to make you feel like the fabric of democracy is unraveling right before our eyes. We're staring at a national identity crisis, folks, and it's got nothing to do with whether you're waving a red or blue flag. This ain't about party lines; it's about a bigger,...

Seatrium & Karpowership Boost Southeast Asia's Energy Future

Anchoring Ambitions: A Fresh Power Pact Seatrium Limited and Karpowership are rolling up their sleeves for a tough yet lucrative mission in Southeast Asia. These two powerhouses are pooling their expertise to beef up the region’s energy supply through floating power solutions and digital infrastructure. You gotta give it to them—they’re not skimping on the ambition....

Grünenthal Pushes Pain Boundaries with RISE Trial Win

Grünenthal, coming straight outta Germany, is lighting up the stage at the 2026 IASP World Congress on Pain in Bangkok with some heavy-duty results from their Phase III RISE trial. We’re talking serious news for folks grappling with post-surgical neuropathic pain. Breaking Down the RISE Results Let’s cut to the chase: Qutenza®, the protagonist here, smashed through...

Navigating Home Care: What Families Need to Know

Peeking into the Home Care Playbook The process of starting home care isn't some mind-boggling puzzle. For families in Northeastern Pennsylvania, things kick off with a cordial chinwag with a care coordinator—no paperwork chains or Kafkaesque contracts right off the bat. Now, if you've got someone in need of care, this gives you time to shove all your questions onto the...

Flagstar Faces Heat: 9.2% Stock Drop Spurs Probe

Flagstar's Descent: What Led to the Stock Tumble? And here we go again with a big name in finance taking a hit right between the eyes. Flagstar Bank, under ticker NYSE:FLG, saw its shares plummet by over 9.2% on October 23, 2026. This isn't just a blip—it's a spill. The backdrop here is an eye-watering $12.9 billion loan book tied to rent-regulated apartment buildings....

Ferrovial's EUR 600M Scrip Dividend: What's Brewing?

Understanding Ferrovial's Latest Financial Maneuver Alright, investors, listen up—Ferrovial's just tossed a hefty EUR 600 million scrip dividend onto the table, giving shareholders the choice between cash or shares. Now, if you've been around the block, this sort of move can mean a few things, and it's best not to treat it like coins rattling in a collection plate. This...

Lear Capital Hits $5 Billion Milestone: Trust or Hype?

A Golden Milestone or Just Glitter? Lear Capital's announcement of surpassing $5 billion in precious metals transactions feels like one of those moments where you tilt your head and ask, "Is it really what it seems?" With nearly 150,000 customers and almost three decades of hustling in the glittering world of gold and silver, they've certainly carved out a name in the...

BAC Shareholders Face Class Action: Fraud Allegations

Legal Storm Brewing Over Bank of America If you thought the banking sector was a safe harbor, folks, take a gander at the latest happening with the Bank of America Corporation (NYSE: BAC). The old titans aren't immune to legal turmoil, as evidenced by the ruckus over a $1.2 billion fine slapped on the bank for violations involving anti-money laundering laws. Now, a...

Oracle Targets US Government With Multicloud AI Plans

Oracle's Ambitious Expansion Into Government Cloud Services Oracle, the tech giant that's seen it all, is charging into the US government and public sector's turf with a bold move to get FedRAMP Class D certification for their AI Database services across major cloud providers. Anyone watching Oracle (NYSE: ORCL) over the years knows they don't make these moves lightly....

Envista's 2025 Sustainability Report: Key Takeaways

Envista's Green Drive: Numbers Tell the Story Whoever said numbers don't lie must've had reports like Envista's 2025 Sustainability Report in mind. This isn't just a glossy PR piece; it's a gritty reveal on how a company can clean house while cranking out progress in dental care. From the heart of Brea, California, Envista Holdings Corporation (NYSE:NVST) proves it's not...